Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

@article{Shah2020BispecificAA,
  title={Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.},
  author={Nirav N. Shah and Bryon D Johnson and Dina Schneider and Fenlu Zhu and Aniko Szabo and Carolyn A Keever-Taylor and Winfried Krueger and Andrew Worden and Michael J. Kadan and Sharon Yim and Ashley M Cunningham and Mehdi Hamadani and Timothy S. Fenske and Boro Dropuli{\'c} and Rimas J. Orentas and Parameswaran N. Hari},
  journal={Nature medicine},
  year={2020}
}
Chimeric antigen receptor (CAR) T cells targeting CD19 are a breakthrough treatment for relapsed, refractory B cell malignancies1-5. Despite impressive outcomes, relapse with CD19- disease remains a challenge. We address this limitation through a first-in-human trial of bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells for relapsed, refractory B cell malignancies. Adult patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated on a phase 1 dose escalation and… 
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
TLDR
The results further implicate antigen loss as a major cause ofCAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
TLDR
CD19/CD22 dual-targeted CAR T cells may be a safe, potent antilymphoma cell-based targeted immunotherapy in patients with relapsed/refractory aggressive B-cell lymphoma.
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
TLDR
This study demonstrates the safety and potential clinical efficacy of bispecific CD19/22 CAR T cells in patients with R/R B-NHL and highlights the importance of measuring kinetic parameters in PB to predict efficacy and safety in clinical applications of CAR T cell therapy.
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
The prognosis for patients with large B-cell lymphoma (LBCL) progressing after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
TLDR
Bispecific BM38 CAR-Ts were feasible, safe and significantly effective in patient with RRMM and exhibited potent antimyeloma activity in xenograft mouse models.
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia
TLDR
The data support clinical translation of BAFF-R/CD19 dual CAR T cells to treat ALL and show prolonged in vivo persistence, raising the possibility that these cells may have the potential to promote durable remissions.
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
TLDR
An anti-CD19 CAR (CAR19) comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains is developed, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
TLDR
CAR-T therapy provides significant potential in the treatment of relapsed B-cell lymphomas despite current limitations, and several novel CAR cell designs are currently being studied in clinical trials.
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma.
ABSTRACT Anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy yields durable remissions in up to 40% of patients with chemoresistant aggressive B-cell non-Hodgkin lymphoma (NHL), a group
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
TLDR
Using the clinically validated NK-92 cell line as a therapeutic cell source, this work established a readily accessible and flexible platform for the generation of highly functional dual-targeted CAR-NK cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma.
TLDR
It is found that TanCAR7 T cells not only showed dual antigen targeting of both CD19 and CD20 but also formed superior and stable immunological synapse (IS) structures, which may be related to their robust antitumor activity.
Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
TLDR
A bi-specific CAR construct targeting CD19 & CD22 with intracellular signaling domains incorporating 4-1BB and CD3ζ (CD19/CD22.z) to overcome CD19 immune escape in adults is developed to determine feasibility of manufacturing the bi- specific CAR and safety at three dose levels.
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
TLDR
This is the first bispecific CAR capable of preventing antigen escape by performing true OR-gate signal computation on a clinically relevant pair of tumor-associated antigens, and the CD19-OR-CD20 CAR is fully compatible with existing T-cell manufacturing procedures and implementable by current clinical protocols.
Mechanisms of resistance to CAR T cell therapy
  • N. Shah, T. Fry
  • Medicine, Biology
    Nature Reviews Clinical Oncology
  • 2019
TLDR
The authors outline the key limitations of CAR T cell therapy, with a focus on mechanisms of resistance, and discuss strategies to improve the efficacy and broaden the applicability of this promising therapeutic approach.
Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas
TLDR
CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B‐cell lymphoma and follicular lymphoma, and high rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients.
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
TLDR
In this cohort of patients relapsing after axi-cel, loss of CD19 expression was common by IHC as compared to pretreatment, likely due to alternative splicing and selection of variants devoid of target epitope, and these data point to strategies to improve efficacy of anti-CD19 CAR T cell products through co-targeting or sequential targeting of alternate B cell antigens.
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
TLDR
Tandem CARs are equally effective in standard disease models to single antigen specificity CARs, and may be both more effective and less toxic in a higher disease burden setting.
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
TLDR
This review will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targetedCAR-T therapies, review identified tumor escape mechanisms, and discuss novel strategies to overcome resistance via multi-targeted CAR- T cells.
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
TLDR
The seamless phase 1 TRANSCEND NHL 001 study evaluated liso-cel in pts with R/R large B cell NHL and presented data with long-term follow-up from pts treated in the DLBCL cohort, finding results were similar between DLs; therefore, data were pooled.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
TLDR
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.
...
1
2
3
4
...